Physician profile

Patrick John Kendell

Family Medicine · Layton, UT

NPI 1225324973

$4,425.64

in general payments reported to CMS, 2019-2025

47 companies · $770 in 2025

The $770 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,845.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $540.56 2019-2025 Evenity, Repatha, Otezla
Abbvie INC. $469.61 2021-2025
Boehringer Ingelheim Pharmaceuticals, INC. $347.71 2019-2025 Jardiance, Tradjenta, Synjardy
Lilly USA, LLC $344.26 2019-2025 Mounjaro, Jardiance, Zepbound
Astrazeneca Pharmaceuticals LP $338.24 2019-2025 Airsupra, Breztri
Glaxosmithkline, LLC. $319.08 2019-2025 Arexvy, Shingrix, Bexsero
E.R. Squibb & Sons, L.L.C. $218.31 2019-2022
Amarin Pharma, INC. $176.06 2020-2022
Pfizer INC. $146.54 2019-2024
Astellas Pharma US INC $135.35 2020-2024 Veozah
Dynavax Technologies Corporation $132.46 2019-2025 Heplisav-B
Janssen Pharmaceuticals, INC $89.18 2019-2024 Spravato
Sanofi-Aventis U.S. LLC $86.85 2019-2025
Arbor Pharmaceuticals, INC. $70.99 2019-2021
Idorsia Pharmaceuticals US INC $57.82 2022-2023 Quviviq
Show all 47 companies
CompanyGeneral paymentsYearsTop products
Allergan, INC. $55.35 2020-2021
Biohaven Pharmaceutical Holding Company LTD. $52.92 2022
Merck Sharp & Dohme LLC $52.76 2019-2023 Verquvo, Steglatro, Belsomra
Sumitomo Pharma America, INC. $52.07 2025 Gemtesa
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $50.85 2022-2025 Caplyta
Supernus Pharmaceuticals, INC. $49.47 2020-2022
Daiichi Sankyo INC. $41.64 2020
Philips North America LLC $36.77 2019-2023
Corcept Therapeutics $36.07 2024 Korlym
Novo Nordisk INC $35.62 2019-2022
Axsome Therapeutics, INC. $34.49 2023 Sunosi
Phathom Pharmaceuticals, INC. $32.87 2025 Voquezna
Kowa Pharmaceuticals America, INC. $30.29 2020-2025 Zoryve
Neurocrine Biosciences, INC. $30.24 2023-2025 Ingrezza
Otsuka America Pharmaceutical, INC. $30.07 2025 Rexulti
Boston Scientific Corporation $27.73 2019-2020
Currax Pharmaceuticals LLC $26.53 2021-2024 Contrave, Onzetra Xsail
Takeda Pharmaceuticals U.S.A., INC. $26.45 2023 Trintellix
Gilead Sciences, INC. $25.96 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $25.59 2019
Dexcom, INC. $24.76 2025 Dexcom G6 Transmitter
Viiv Healthcare Company $23.10 2024 Apretude
Eisai INC. $22.58 2020-2021
Bayer Healthcare Pharmaceuticals INC. $17.02 2024
Biogen, INC. $16.07 2021
Biohaven Pharmaceuticals, INC. $14.62 2021
Genentech USA, INC. $14.10 2021
Medtronic, INC. $13.96 2022
Lundbeck LLC $13.43 2023 Rexulti
Lucid Diagnostics INC. $13.26 2023
Ultragenyx Pharmaceutical INC. $13.22 2022
Neurelis, INC. $12.76 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patrick John Kendell

$4,425.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $770 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/768585/patrick-john-kendell

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.